Holen Sie sich die Stockscreener-App
2.37
1.28%
0.02
Schlusskurs vom Vortag:
$2.35
Offen:
$2.32
24-Stunden-Volumen:
73,437
Relative Volume:
0.21
Marktkapitalisierung:
$101.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-2.85%
1M Leistung:
-17.93%
6M Leistung:
-54.58%
1J Leistung:
-89.76%
1-Tages-Spanne:
$2.29
$2.385
1-Wochen-Bereich:
$2.20
$2.47
52-Wochen-Spanne:
$2.20
$25.84
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Firmenname
Kyverna Therapeutics Inc
Sektor
Branche
Telefon
(510) 626-8331
Adresse
5980 HORTON STREET, EMERYVILLE
Vergleichen Sie KYTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
2.38 | 101.45M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
510.51 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
653.88 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
287.68 | 37.54B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ARGX
Argen X Se Adr
|
606.47 | 37.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ONC
Beigene Ltd Adr
|
252.18 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-10-09 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-07-03 | Eingeleitet | H.C. Wainwright | Neutral |
| 2024-03-04 | Eingeleitet | JP Morgan | Overweight |
| 2024-03-04 | Eingeleitet | Leerink Partners | Outperform |
| 2024-03-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-03-04 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Kyverna Therapeutics Inc Aktie (KYTX) Neueste Nachrichten
Notice to Long-Term Shareholders of Akero Therapeutics, - GlobeNewswire
Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is I - TradingView
Why Kyverna Therapeutics Stock Is Sinking - MSN
Investors Who Lost Money on Kyverna Therapeutics, Inc. (KYTX) Should Contact Levi & Korsinsky About Pending Class ActionKYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More Information – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights – KYTX - ACCESS Newswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire
Kyverna Therapeutics Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
Kyverna Therapeutics stock hits 52-week low at $2.24 - Investing.com
Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 - Seeking Alpha
Kyverna Therapeutics stock hits 52-week low at $2.24 By Investing.com - Investing.com South Africa
Notice to Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Clai - Morningstar
Kyverna Therapeutics (KYTX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lupus Nephritis Clinical and Non-Clinical Studies, Key - openPR
GordonMD® Invests in Clinical Stage Cell Therapy Company Kyverna - Business Wire
Notice to Long-Term Shareholders of Archer-Daniels-Midland - GlobeNewswire
Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Notice to Long-Term Shareholders of Fluence Energy, Inc. - GlobeNewswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: - GlobeNewswire
KYTX stock touches 52-week low at $2.49 amid market challenges - Investing.com Australia
Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Rhumbline Advisers Purchases 6,153 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - Defense World
Kyverna Therapeutics stock hits 52-week low at $2.64 By Investing.com - Investing.com Australia
Kyverna Therapeutics to Present at the Leerink Partners Global B - GuruFocus.com
Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference - PR Newswire
Kyverna Therapeutics stock hits 52-week low at $2.64 - Investing.com
Levi & Korsinsky Notifies Shareholders of Kyverna Therapeutics, Inc. (KYTX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Kyverna Therapeutics To Present At The Leerink Partners Global Biopharma Conference - MENAFN.COM
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Head-To-Head Survey: Pluri (NASDAQ:PLUR) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. LawsuitKYTX - ACCESS Newswire
3 US Penny Stocks With Market Caps Under $200M - Yahoo Finance
KYTX stock touches 52-week low at $2.78 amid sharp annual decline - MSN
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $25.71 Consensus Price Target from Analysts - Defense World
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Leerink Partnrs Issues Optimistic Estimate for KYTX Earnings - MarketBeat
KYTX stock touches 52-week low at $2.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Equities Analysts Set Expectations for KYTX FY2025 Earnings - Defense World
What Makes Kyverna Therapeutics, Inc. (KYTX) a New Buy Stock - MSN
KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit - Morningstar
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - Kilgore News Herald
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadli - GuruFocus.com
2025-02-07 | FINAL REMINDER KYTX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Kyverna Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit | NDAQ:KYTX | Press Release - Stockhouse Publishing
The Gross Law Firm Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - PR Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - TradingView
Finanzdaten der Kyverna Therapeutics Inc-Aktie (KYTX)
Es liegen keine Finanzdaten für Kyverna Therapeutics Inc (KYTX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Kyverna Therapeutics Inc-Aktie (KYTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Jones Ryan Alexander | Chief Financial Officer |
May 28 '24 |
Option Exercise |
0.73 |
18,016 |
13,152 |
43,950 |
1.39%
0.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):